News | Left Atrial Appendage (LAA) Occluders | March 16, 2016

Valley Hospital Begins Enrollment for aMAZE Trial

New Jersey hospital one of 15 U.S. sites for trial evaluating Lariat suture delivery device for treatment of atrial fibrillation

aMAZE Trial enrollment, The Valley Hospital NJ, atrial fibrillation

March 16, 2016 — The Valley Hospital in Ridgewood, N.J., is one of 15 U.S. sites currently enrolling patients in a research study evaluating a potential new treatment for patients with symptomatic persistent and long standing persistent atrial fibrillation (AFib).

The aMAZE Trial is evaluating an innovative treatment approach that combines catheter ablation with the use of a device called the Lariat to close off the heart’s left atrial appendage (LAA). Just as the name implies, the Lariat uses a lasso-like stitch to tie off the LAA — a muscular pouch connected to the left atrium of the heart that is the major source of blood clots in patients with atrial fibrillation that can lead to a stroke. The LAA may also be a source of abnormal electrical activity that triggers AFib. The trial will evaluate whether the combination of the two treatment approaches may treat persistent AFib more effectively than catheter abolition alone.

“We are pleased to be one of the first sites in the U.S. to enroll patients in the aMAZE Trial,” said Dan Musat, M.D., principal investigator for the aMAZE Trial at Valley. “We are optimistic that we will be able to show that combining the two approaches is an effective option for patients with persistent AFib.”

AFib is an irregular heartbeat, a rapid heartbeat or a quivering of the upper chambers of the heart, called the atria, due to a malfunction in the heart's electrical system. It is the most common heart rhythm disorder in the United States, affecting more than 5 million people. Because the heart is not beating effectively, blood can pool in the upper chambers of the heart and form a clot, typically in the left atrial appendage. If the clot then travels from the heart to the brain, it can cause a stroke.

“This is a potential milestone in the treatment of atrial fibrillation” said Suneet Mittal, M.D., director of electrophysiology at Valley. “AFib is a life-changing disorder that causes devastating consequences, including stroke and congestive heart failure. Using the Lariat device as an adjunct to conventional ablation could become the standard of care for patients with persistent and/or long-standing persistent AFib.”

In a recently published study, the Lariat used as an adjunct to ablation in patients with persistent or long-standing persistent AFib showed a 65 percent freedom from AFib at one year compared with 39 percent in patients with ablation alone. Other studies have demonstrated that the device not only closes the LAA mechanically, but can also isolate electrical activity within the LAA — a known trigger for AFib, shown to contribute abnormal electrical activity in a significant percentage of patients.

The objective of the aMAZE trial is to demonstrate that the Lariat will reduce or eliminate these LAA triggers and, when combined with ablation, will lead to a reduced incidence of recurrent AFib compared to ablation alone, with a high safety profile.

The Lariat is a permanent, non-implant solution to LAA closure that is being studied for its capabilities to both mechanically and electrically isolate the LAA in patients with AFib. The device utilizes remote suture delivery to close the LAA from the outside of the heart in a precise and controlled manner.

The aMAZE trial is comprised of two stages. The overall study plan is to enroll a maximum of 600 persistent or longstanding persistent AFib patients who are candidates for catheter ablation at up to 50 centers. The first stage of the trial, underway now, will enroll up to 175 patients at 15 centers.

For more information:

Related Content

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell
The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant
Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018
The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the launch of a free, online...
The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS
When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation
Acutus dipole density EP mapping for ablation procedures.

The FDA recently cleared high-speed Acutus Medical's AcQMap High Resolution image and mapping system and the AcQMap 3-D Imaging and Mapping Catheter.  detects and displays both standard voltage-based and higher resolution dipole density (charge-source) maps. The system combines ultrasound anatomy construction with an ability to map the electrical-conduction of each heartbeat to identify complex arrhythmias across the entire atrial chamber. Following each ablation treatment, the heart can be re-mapped in seconds to continually visualize any changes from the prior mapping.



Feature | Atrial Fibrillation | November 07, 2017
November 7, 2017 — Here is an aggregated list of articles detailing the latest clinical data and new device technolog
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the B
UNC School of Medicine Receives $1.7 Million for Atrial Fibrillation Program Streamlining Patient Care
News | Atrial Fibrillation | October 23, 2017
October 23, 2017 — University of North Carolina (UNC) School of Medicine cardiologist Anil Gehi, M.D., will use a $1.
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation | September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Overlay Init